Haipeng Li1, Kiyoshi Itagaki, Nicola Sandler, David Gallo, Amanda Galenkamp, Elzbieta Kaczmarek, David H Livingston, Yi Zeng, Yen Ting Lee, I Tien Tang, Burak Isal, Leo Otterbein, Carl J Hauser. 1. From the Department of Surgery (H.L., K.I., N.S., D.G., A.G., E.K., L.O., C.J.H.), Center for Vascular Biology Research (E.K.), and R&AA-Morphology Core (Y.Z.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; Rutgers New Jersey Medical School (D.H.L.), Newark, New Jersey; Department of Orthopaedics (H.L.), Beijing Army General Hospital, Beijing, China; National Yang Ming University (Y.T.L., I.T.T.), Taipei, Taiwan; and Istanbul University Cerrahpasa Medical Faculty (B.I.), Istanbul, Turkey.
Abstract
BACKGROUND: No known biologic mechanisms link tissue injury with pneumonia (PNA). Neutrophils (PMNs) are innate immune cells that clear bacteria from the lung by migration toward chemoattractants and killing bacteria in neutrophil extracellular traps (NETs). We predicted that tissue injury would suppress PMN antimicrobial function in the lung. We have also shown that mitochondria-derived damage-associated molecular pattern molecules from the bone can alter PMN phenotype and so hypothesized that formyl peptides (FPs) from fractures predispose to PNA by suppressing PMN activity in the lung. METHODS: Animal studies involved the following. (1) Rats were divided into three groups (10 per condition) as follows: (a) saline injection in the thigh (b) Staphylococcus aureus (SA, 3 × 10) injected intratracheally, or (c) pseudofracture (PsFx; bone supernatant injected in the thigh) plus intratracheally injected SA. (2) Rats were divided into four groups as follows: (a) control, (b) pulmonary contusion (PC), (c) PsFx, and (d) PC + PsFx. Bronchoalveolar lavage was performed 16 hours later. Clinical studies involved the following. (3) Human bone supernatant was assayed for its FP-receptor (FPR) stimulation. (4) Trauma patients' PMN (n = 32; mean ± SE Injury Severity Score [ISS], 27 ± 10) were assayed for chemotaxis (CTX) or treated with Phorbol 12-myristate 13-acetate (PMA, Phorbol ester) and analyzed for NET formation. RESULTS: In the animal studies, (1) SA was rapidly cleared by the uninjured mice and PsFx markedly suppressed lung bacterial clearance (p < 0.01). (2a) PC induces PMN traffic to the lung, but PsFx decreases PC-induced PMN traffic (p < 0.01). (2b) SA increased bronchoalveolar lavage PMN, and PsFx decreased that influx (p < 0.01). In the clinical studies, (3) bone supernatant activates PMN both via FPR-1 and FPR-2. (4) Trauma decreases PMN CTX to multiple chemokines. Circulating PMNs show NETs spontaneously after trauma, but maximal NET formation is markedly attenuated. CONCLUSION: Fractures may decrease lung bacterial clearance because FP suppresses PMN CTX to other chemoattractants via FPR-1/2. Trauma activates NETosis but suppresses maximal NETosis. Fractures decrease lung bacterial clearance by multiple mechanisms. PNA after fractures may reflect damage-associated molecular pattern-mediated suppression of PMN antimicrobial function in the lung.
BACKGROUND: No known biologic mechanisms link tissue injury with pneumonia (PNA). Neutrophils (PMNs) are innate immune cells that clear bacteria from the lung by migration toward chemoattractants and killing bacteria in neutrophil extracellular traps (NETs). We predicted that tissue injury would suppress PMN antimicrobial function in the lung. We have also shown that mitochondria-derived damage-associated molecular pattern molecules from the bone can alter PMN phenotype and so hypothesized that formyl peptides (FPs) from fractures predispose to PNA by suppressing PMN activity in the lung. METHODS: Animal studies involved the following. (1) Rats were divided into three groups (10 per condition) as follows: (a) saline injection in the thigh (b) Staphylococcus aureus (SA, 3 × 10) injected intratracheally, or (c) pseudofracture (PsFx; bone supernatant injected in the thigh) plus intratracheally injected SA. (2) Rats were divided into four groups as follows: (a) control, (b) pulmonary contusion (PC), (c) PsFx, and (d) PC + PsFx. Bronchoalveolar lavage was performed 16 hours later. Clinical studies involved the following. (3) Human bone supernatant was assayed for its FP-receptor (FPR) stimulation. (4) Traumapatients' PMN (n = 32; mean ± SE Injury Severity Score [ISS], 27 ± 10) were assayed for chemotaxis (CTX) or treated with Phorbol 12-myristate 13-acetate (PMA, Phorbol ester) and analyzed for NET formation. RESULTS: In the animal studies, (1) SA was rapidly cleared by the uninjured mice and PsFx markedly suppressed lung bacterial clearance (p < 0.01). (2a) PC induces PMN traffic to the lung, but PsFx decreases PC-induced PMN traffic (p < 0.01). (2b) SA increased bronchoalveolar lavage PMN, and PsFx decreased that influx (p < 0.01). In the clinical studies, (3) bone supernatant activates PMN both via FPR-1 and FPR-2. (4) Trauma decreases PMN CTX to multiple chemokines. Circulating PMNs show NETs spontaneously after trauma, but maximal NET formation is markedly attenuated. CONCLUSION:Fractures may decrease lung bacterial clearance because FP suppresses PMN CTX to other chemoattractants via FPR-1/2. Trauma activates NETosis but suppresses maximal NETosis. Fractures decrease lung bacterial clearance by multiple mechanisms. PNA after fractures may reflect damage-associated molecular pattern-mediated suppression of PMN antimicrobial function in the lung.
Authors: Michael H Tarlowe; Andrew Duffy; Kollenkode B Kannan; Kiyoshi Itagaki; Robert F Lavery; David H Livingston; Paul Bankey; Carl J Hauser Journal: Am J Respir Crit Care Med Date: 2004-12-23 Impact factor: 21.405
Authors: Kiyoshi Itagaki; K B Kannan; David H Livingston; Edwin A Deitch; Zoltan Fekete; Carl J Hauser Journal: J Immunol Date: 2002-04-15 Impact factor: 5.422
Authors: Matthew J Eckert; Kimberly A Davis; R Lawrence Reed; John M Santaniello; Stathis Poulakidas; Thomas J Esposito; Fred A Luchette Journal: J Trauma Date: 2004-10
Authors: Chirag D Badami; David H Livingston; Ziad C Sifri; Francis J Caputo; Larissa Bonilla; Alicia M Mohr; Edwin A Deitch Journal: J Trauma Date: 2007-09
Authors: Sadani N Cooray; Thomas Gobbetti; Trinidad Montero-Melendez; Simon McArthur; Dawn Thompson; Adrian J L Clark; Roderick J Flower; Mauro Perretti Journal: Proc Natl Acad Sci U S A Date: 2013-10-09 Impact factor: 11.205
Authors: Michael H Tarlowe; K B Kannan; Kiyoshi Itagaki; John M Adams; David H Livingston; Carl J Hauser Journal: J Immunol Date: 2003-08-15 Impact factor: 5.422
Authors: Terry Hsieh; Max H Vaickus; Thor D Stein; Bethany L Lussier; Jiyoun Kim; David M Stepien; Elizabeth R Duffy; Evan L Chiswick; Daniel G Remick Journal: Am J Pathol Date: 2016-12 Impact factor: 4.307
Authors: Kiyoshi Itagaki; Elzbieta Kaczmarek; Woon Yong Kwon; Li Chen; Barbora Vlková; Quanzhi Zhang; Ingred Riça; Michael B Yaffe; Yan Campbell; Michael F Marusich; Ji Ming Wang; Wang-Hua Gong; Ji-Liang Gao; Françoise Jung; Garry Douglas; Leo E Otterbein; Carl J Hauser Journal: Crit Care Med Date: 2020-02 Impact factor: 7.598
Authors: Yann-Leei Lee; Boniface Obiako; Olena M Gorodnya; Mykhaylo V Ruchko; Jamie L Kuck; Viktor M Pastukh; Glenn L Wilson; Jon D Simmons; Mark N Gillespie Journal: Shock Date: 2017-07 Impact factor: 3.454
Authors: Jon Hazeldine; David N Naumann; Emma Toman; David Davies; Jonathan R B Bishop; Zhangjie Su; Peter Hampson; Robert J Dinsdale; Nicholas Crombie; Niharika Arora Duggal; Paul Harrison; Antonio Belli; Janet M Lord Journal: PLoS Med Date: 2017-07-18 Impact factor: 11.069